MedTrace Logo

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

NCT07227909 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2026-05-22

No results posted yet for this study

Summary

To learn if psilocybin can help to prevent or decrease the severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients who are receiving chemotherapy for the treatment of breast, colorectal, and In this study, psilocybin is being compared to standard supportive care and to a placebo.

Conditions

Interventions

DRUG

Psilocybin (drug)

Given by po 25 mg

DRUG

Psilocybin (drug)

Given by po 1mg

OTHER

Standard of Care (SOC)

No drug

Sponsors & Collaborators

  • Usona Institute

    collaborator OTHER

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Moran Amit, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-04
Primary Completion
2029-01-31
Completion
2031-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07227909 on ClinicalTrials.gov